Is There Already a Need of Reckoning on Cancer Immunotherapy?
Main Authors: | Pierpaolo Correale, Francesca Pentimalli, Giovanni Baglio, Marjia Krstic-Demonacos, Rita Emilena Saladino, Antonio Giordano, Luciano Mutti |
---|---|
格式: | Article |
語言: | English |
出版: |
Frontiers Media S.A.
2021-03-01
|
叢編: | Frontiers in Pharmacology |
主題: | |
在線閱讀: | https://www.frontiersin.org/articles/10.3389/fphar.2021.638279/full |
相似書籍
-
Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
由: Luciano Mutti, et al.
出版: (2020-05-01) -
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
由: Roger Y. Kim, MD, et al.
出版: (2021-06-01) -
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
由: Francesca Pentimalli, et al.
出版: (2023-03-01) -
Current status and progress in immunotherapy for malignant pleural mesothelioma
由: Boyang Sun, et al.
出版: (2022-06-01) -
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
由: Valerio Nardone, et al.
出版: (2021-11-01)